Cancer Letters
Volume 220, Issue 1 , Pages 37-48 , 18 March 2005

Structure–activity relationships of quassinoids for eukaryotic protein synthesis

  • Narihiko Fukamiya

      Affiliations

    • Faculty of Integrated Arts and Sciences, Hiroshima University, Kagamiyama 1-7-1, Higashi, Hiroshima 739-8521, Japan
    • ,
  • Kuo-Hsiung Lee

      Affiliations

    • Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    • ,
  • Ilias Muhammad

      Affiliations

    • National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA
    • ,
  • Chihiro Murakami

      Affiliations

    • Faculty of Integrated Arts and Sciences, Hiroshima University, Kagamiyama 1-7-1, Higashi, Hiroshima 739-8521, Japan
    • ,
  • Masayohis Okano

      Affiliations

    • Faculty of Integrated Arts and Sciences, Hiroshima University, Kagamiyama 1-7-1, Higashi, Hiroshima 739-8521, Japan
    • ,
  • Isabelle Harvey

      Affiliations

    • Dept. of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montreal, Que., Canada H3G 1Y6
    • ,
  • Jerry Pelletier

      Affiliations

    • Dept. of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montreal, Que., Canada H3G 1Y6
    • McGill Cancer Center, McIntyre Medical Sciences Building, McGill University, Montreal, Que., Canada H3G 1Y6
    • Corresponding Author InformationCorresponding author. Address: McIntyre Medical Sciences Building, McGill University, Montreal, Que., Canada H3G 1Y6. Tel.: +1-514-398-2323; fax: +1-514-398-7384

Received 26 April 2004 ,Accepted 27 April 2004.

References 

  1. Watkins SJ, Norbury CJ. Translation initiation and its deregulation during tumorigenesis. Br. J. Cancer. 2002;86:1023–1027
  2. Graff JR, Zimmer SG. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Met. 2003;20:265–273
  3. Hershey JWB, Miyamoto S. Translational control and cancer. In:  Sonenberg N,  Hershey JWB,  Mathews MB editor. Translational Control of Gene Expression. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2000;p. 637–654
  4. Anand N, Murthy S, Amann G, Wernick M, Porter LA, Cukier IH, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat. Genet. 2002;31:301–305
  5. Tarbe N, Evtimova V, Burtscher H, Jarsch M, Alves F, Weidle UH. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res. 2001;21:3221–3228
  6. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, et al. The gene encoding ribosomal protein S19 is mutated in Diamond–Blackfan anaemia. Nat. Genet. 1999;21:169–175
  7. Cavanaugh AH, Hempel WM, Taylor LJ, Rogalsky V, Todorov G, Rothblum LI. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature. 1995;374:177–180
  8. Ciarmatori S, Scott PH, Sutcliffe JE, McLees A, Alzuherri HM, Dannenberg JH, et al. Overlapping functions of the pRb family in the regulation of rRNA synthesis. Mol. Cell. Biol. 2001;21:5806–5814
  9. Ruggero D, Pandolfi PP. Does the ribosome translate cancer?. Nat. Rev. 2003;3:179–192
  10. Meric F, Hunt KK. Translation Initiation in Cancer: A Novel Target for Therapy. Mol. Cancer Ther. 2003;1:971–979
  11. Holcik M, Korneluk RG. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: role of La autoantigen in XIAP translation. Mol. Cell. Biol. 2000;20:4648–4657
  12. Wendel H-G, de Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337
  13. Kupchan SM, Britton RW, Ziegler MF, Sigel CW. Bruceantin, a new potent antileukemic simaroubolide from Brucea antidysenterica. J. Org. Chem. 1973;38:178–179
  14. Kupchan SM, Britton RW, Lacadie JA, Ziegler MF, Sigel CW. The isolation and structural elucidation of bruceatin and bruceantinol, new potent antileukemic quassinoids from Brucea antidysenterica. J. Org. Chem. 1975;40:648–654
  15. Pierré A, Robert-Géro M, Tempête C, Polonsky J. Structural requirements of quassinoids for the inhibition of cell transformation. Biochem. Biophys. Res. Commun. 1980;93:675–686
  16. Guru PY, Warhurst DC, Harris A, Phillipson JD. Antimalaria activity of bruceantin in vitro. Ann. Trop. Med. Parasit. 1983;77:433–435
  17. Liao L-L, Kupchan SM, Horwitz SB. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol. Pharm. 1976;12:167–176
  18. Fresno M, Gonzales A, Vazquez D, Jimenez A. Bruceantin, a novel inhibitor of peptide formation. Biochim. Biophys. Acta. 1978;518:104–112
  19. Willingham W, Considine RT, Chaney SG, Lee K-H, Hall IH. Reversibility of protein synthesis inhibition by quassinoid antineoplastic agents in a rabbit reticulocyte system. Biochem. Pharm. 1981;33:330–333
  20. Liou YF, Hall IH, Okano M, Lee K-H, Chaney SG, Antitumor SG. Agents XLVIII: Structure-activity relationships of quassinoids as in vitro protein synthesis inhibitors of P-388 lymphocytic leukemia tumor cell metabolism. J. Pharm. Sci. 1982;71:430–435
  21. Considine RT, Willingham W, Chaney SG, Wyrick S, Hall IH, Lee K-H. Structure-activity relationships for binding and inactivation of rabbit reticulocyte ribosomes by quassinoid antineoplastic agents. Eur. J. Biochem. 1983;132:157–163
  22. Rodriguez-Fonseca C, Amils R, Garrett RA. Fine structure of the peptidyl transferase centre on 23S-like rRNAs deduced from chemical probing of antibiotic-ribosome complexes. J. Mol. Biol. 1995;247:224–235
  23. Jimenez A, Vazquez D. Quantitative binding of antibiotics to ribosomes from a yeast mutant altered on the peptidyl-transferase center. Eur. J. Biochem. 1975;54:483–492
  24. Mata-Greenwood E, Cuendet M, Sher D, Gustin D, Stock W, Pezzuto JM. Brusatol-mediated induction of leukemic cell differentiation and G(1) arrest is associated with down-regulation of c-myc. Leukemia. 2002;16:2275–2284
  25. Cuendet M, Pezzuto JM. Antitumor activity of bruceantin: an old drug with new promise. J. Nat. Prod. 2004;67:269–272
  26. Cuendet M, Gills JJ, Pezzuto JM. Brusatol-induced HL-60 cell differentiation involves NF-kB activation. Cancer Lett. 2004;206:43–50
  27. Liesmann J, Belt RJ, Haas CD, Hoogstraten B. Phase I study on bruceantin administered on a weekly schedule. Cancer Treat. Rep. 1981;65:883–885
  28. Bedikian AY, Valdivieso M, Bodey GP, Murphy WK, Freireich EJ. Initial clinical studies with bruceantin. Cancer Treat. Rep. 1979;63:1843–1847
  29. Wiseman CL, Yap HY, Bedikian AY, Bodey GP, Blumenschein GR. Phase II trial of bruceantin in metastatic breast carcinoma. Am. J. Clin. Oncol. 1982;5:389–391
  30. Arseneau JC, Wolter JM, Kuperminc M, Ruckdeschel JC. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma. Invest. New Drugs. 1983;1:239–242
  31. Sambrook J, Russell DW. Molecular Cloning. A laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor laboratory Press; 2001;
  32. Okana M, Fukamiya N, Lee KH. In:  Rahman A editors. Biologically active compounds from Simaroubaceous plants. Studies in Natural Products Chemistry. vol. 7:Amsterdam: Elsevier; 1990;p. 369–404
  33. Okano M, Fukamiya N, Lee KH. In:  Rahman A editors. Bioactive quassinoids. Studies in Natural Products Chemistry. vol. 23:Amsterdam: Elsivier; 2000;p. 285–333
  34. Novac O, Guenier A-S, Pelletier J. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucl. Acids Res. 2004;32:902–915
  35. Svitkin YV, Sonenberg N. In:  Schoenberg DR editors. An efficient system for cap- and poly A -dependent translation in vitro. mRNA Processing and Metabolism. Totowa, NJ: Humana; 2004;p. 155–170
  36. Hall IH, Lee K-H, Eigebaly SA, Imakura Y, Sumida Y, Wu RY. Antitumor agents XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J. Pharm. Sci. 1979;68:883–887
  37. Lee K-H, Okano M, Hall IH, Brent DA, Soltmann B. Antitumor agents XKV: Bisbrusatolyl and brusatolyl esters and related compounds as novel potent antileukemic agents. J. Pharm. Sci. 1982;71:338–345
  38. Hall IH, Liou YF, Okano M, Lee K-H. Antitumor agents XLVI: In vitro effects of esters of brusatol, bisbrusatol, and related compounds on nucleic acid and protein synthesis of P-388 lymphocytic leukemia cells. J. Pharm. Sci. 1982;71:345–348
  39. Mata-Greenwood E, Daeuble JF, Grieco PA, Dou J, McChesney JD, Mehta RG, et al. Novel esters of glaucarubolone as inducers of terminal differentiation of promyelocytic HL-60 cells and inhibitors of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesion formation in mouse mammary organ culture. J. Nat. Prod. 2001;64:1509–1513
  40. O'Neill MJ, Bray DH, Boardman P, Phillipson JD, Warhurst DC, Peters W, et al. Plants as sources of antimalaria drugs: In vitro antimalarial activities of some quassinoids. Antimicro. Agents Chemother. 1986;30:101–104

PII: S0304-3835(04)00373-8

doi: 10.1016/j.canlet.2004.04.023

Cancer Letters
Volume 220, Issue 1 , Pages 37-48 , 18 March 2005

Article Tools

* Image Usage & Resolution